Adverum

ADVM NASDAQ
11.45
-0.05
-0.43%
After Hours: 11.45 0 0.00% 17:29 06/20 EDT
Open
11.58
Prev Close
11.50
High
11.95
Low
11.36
Volume
502.45K
Avg Vol (3M)
633.80K
52 Week High
12.10
52 Week Low
2.620
% Turnover
0.79%
Market Cap
730.29M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Adverum ADVM stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.
MORE >

Recently

Name
Price
%Change